CRNX Stock Price, Crinetics Pharmaceuticals Quote, Chart

Market Summary

USD47.98-0.02

Market Closed

-0.04%

CRNX Alerts

2 major insider sales recently.

CRNX Stock Price

View Fullscreen

CRNX RSI Chart

CRNX Valuation

Market Cap

3.8B

Price/Earnings (Trailing)

-16.07

Price/Sales (Trailing)

1.9K

Price/Free Cashflow

-20.51

CRNX Price/Sales (Trailing)

CRNX Profitability

Return on Equity

-26.91%

Return on Assets

-24.07%

Free Cashflow Yield

-4.87%

CRNX Fundamentals

CRNX Revenue

Revenue (TTM)

2.0M

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

CRNX Earnings

Earnings (TTM)

-235.5M

Earnings Growth (Yr)

-45.52%

Earnings Growth (Qtr)

-11.37%

Breaking Down CRNX Revenue

Last 7 days

3.2%

Last 30 days

7.6%

Last 90 days

33.3%

Trailing 12 Months

116.2%

How does CRNX drawdown profile look like?

CRNX Financial Health

Current Ratio

17.72

CRNX Investor Care

Shares Dilution (1Y)

45.97%

Diluted EPS (TTM)

-3.77

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	2.0M	0	0	0
2023	4.3M	4.8M	4.7M	4.0M
2022	2.0M	2.9M	3.8M	4.7M
2021	0	0	0	1.1M
2020	897.0K	897.0K	392.0K	735.0K
2019	2.4M	1.7M	1.7M	1.2M
2018	2.4M	2.3M	2.2M	2.4M
2017	953.0K	1.3M	1.7M	2.0M
2016	0	0	0	589.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Crinetics Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 08, 2024	struthers richard scott	acquired	997,117	9.28	107,448	president & ceo
May 08, 2024	struthers richard scott	sold	-5,307,930	49.4	-107,448	president & ceo
Apr 18, 2024	struthers richard scott	gifted	-	-	-350	president & ceo
Apr 15, 2024	pizzuti dana	sold	-639,256	44.47	-14,375	chief med and dev officer
Apr 15, 2024	struthers richard scott	acquired	38,200	1.91	20,000	president & ceo
Apr 15, 2024	pizzuti dana	acquired	242,794	16.89	14,375	chief med and dev officer
Apr 04, 2024	struthers richard scott	sold	-2,013,560	49.17	-40,951	president & ceo
Apr 04, 2024	struthers richard scott	acquired	380,025	9.28	40,951	president & ceo
Mar 28, 2024	okey stephanie	acquired	320,075	18.29	17,500	-
Mar 28, 2024	okey stephanie	sold	-811,650	46.38	-17,500	-

Which funds bought or sold CRNX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	BlackRock Inc.	added	1.7	64,284,900	254,464,000	0.01%
May 10, 2024	WELLS FARGO & COMPANY/MN	added	228	2,477,280	3,222,400	-%
May 10, 2024	JPMORGAN CHASE & CO	added	303	14,287,300	17,599,900	-%
May 10, 2024	AJOVista, LLC	sold off	-100	-57,995	-	-%
May 10, 2024	OSAIC HOLDINGS, INC.	reduced	-82.61	-451,368	133,968	-%
May 10, 2024	Pacer Advisors, Inc.	new	-	47,325	47,325	-%
May 10, 2024	CREDIT SUISSE AG/	added	22.43	1,069,970	2,822,030	-%
May 10, 2024	Hillsdale Investment Management Inc.	new	-	6,085	6,085	-%
May 10, 2024	Y-Intercept (Hong Kong) Ltd	sold off	-100	-239,738	-	-%
May 10, 2024	PNC Financial Services Group, Inc.	added	1,850	5,264	5,477	-%

Are Funds Buying or Selling CRNX?

Are funds buying CRNX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CRNX

No. of Funds

CRNX Alerts

2 major insider sales recently.

Unveiling Crinetics Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 11, 2024	ecor1 capital, llc	5.3%	4,155,375	SC 13G
Mar 01, 2024	perceptive advisors llc	1.9%	1,488,703	SC 13D/A
Feb 14, 2024	braidwell lp	0%	0	SC 13G/A
Feb 14, 2024	driehaus capital management llc	7.54%	5,039,477	SC 13G/A
Feb 14, 2024	biotechnology value fund l p	-	0	SC 13G/A
Feb 14, 2024	point72 asset management, l.p.	5.1%	3,416,900	SC 13G/A
Feb 14, 2024	orbimed advisors llc	2.5%	1,667,360	SC 13G/A
Feb 13, 2024	vanguard group inc	5.24%	3,502,452	SC 13G
Feb 09, 2024	fmr llc	-	0	SC 13G
Feb 08, 2024	wellington management group llp	4.86%	3,245,105	SC 13G/A

Recent SEC filings of Crinetics Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 10, 2024	144	Notice of Insider Sale Intent
May 10, 2024	4	Insider Trading
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
May 08, 2024	144	Notice of Insider Sale Intent
May 08, 2024	8-K	Current Report
Apr 25, 2024	ARS	ARS
Apr 25, 2024	DEF 14A	DEF 14A
Apr 25, 2024	DEFA14A	DEFA14A
Apr 22, 2024	4	Insider Trading

Peers (Alternatives to Crinetics Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.2B	6.8B	19.54%	-2.80%	-8.07	7.03	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.0B	2.0B	0.98%	-26.98%	-57.12	9.47	75.20%	68.82%
BMRN	15.3B	2.5B	-12.72%	-14.31%	74.39	6.18	13.74%	186.89%
INCY	12.9B	3.8B	6.98%	-11.75%	17.35	3.43	8.58%	129.81%
MID-CAP
BBIO	5.3B	107.9M	6.22%	110.41%	-9.76	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-16.95%	-51.10%	-12.51	9.96	394.93%	39.61%
AXSM	3.6B	251.0M	9.36%	-4.29%	-12.12	14.31	73.58%	-86.73%
ARWR	2.7B	240.7M	-10.69%	-43.90%	-5.82	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.5K	3.08	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.44	4.66	60.38%	-34.49%
NVAX	1.8B	996.6M	206.31%	55.15%	-4.62	1.85	-26.66%	65.49%
CRBP	458.7M	881.7K	5.07%	336.18%	-13.59	481.06	-77.61%	33.36%
INO	294.6M	4.9M	3.08%	29.79%	-2.36	60.54	-54.97%	48.23%
IBIO	15.6M	2.1M	-10.40%	79.21%	-0.67	7.61	-13.45%	69.54%

Crinetics Pharmaceuticals Inc News

Latest updates

Crinetics Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Revenue	-	640,000	-	346,000	988,000	2,679,000	709,000	458,000	439,000	3,131,000	2,087,333	1,043,667	-	-	71,000	321,000	505,000	-	367,000	781,000	548,000	657,000
Operating Expenses	18.4%	74,169,000	62,658,000	59,323,000	53,983,000	50,657,000	48,265,000	43,912,000	43,484,000	36,958,000	31,966,000	21,791,000	18,451,000	16,929,000	17,853,000	15,535,000	15,734,000	13,345,000	10,411,000	10,212,000	8,618,000	6,340,000
S&GA Expenses	-100.0%	-	17,078,000	15,484,000	13,343,000	12,189,000	11,274,000	11,925,000	10,489,000	8,706,000	7,362,000	4,961,000	4,752,000	4,322,000	3,991,000	3,392,000	3,911,000	3,060,000	3,156,000	2,561,000	1,732,000	1,118,000
R&D Expenses	17.0%	53,341,000	45,580,000	43,839,000	40,640,000	38,468,000	36,991,000	31,987,000	32,995,000	28,252,000	24,604,000	16,830,000	13,699,000	12,607,000	13,862,000	12,143,000	11,823,000	10,285,000	7,255,000	7,651,000	6,886,000	5,222,000
EBITDA Margin	-	-	-	-	-	-	-	-	-14.95	-8.52	-99.00	-1,026	-126	-55.16	-55.18	-41.51	-15.87	-15.52	-11.26	-	-	-
EBT Margin	-	-	-	-	-	-	-	-	-15.08	-8.59	-99.85	-1,039	-128	-56.21	-56.21	-42.26	-16.40	-15.99	-11.52	-	-	-
Net Income	-11.4%	-66,930,000	-60,097,000	-57,458,000	-50,979,000	-45,995,000	-44,991,000	-41,925,000	-42,375,000	-34,627,000	-30,794,000	-21,641,000	-18,320,000	-16,491,000	-17,360,000	-14,549,000	-14,430,000	-12,427,000	-9,016,000	-8,495,000	-7,588,000	-5,568,000
Net Income Margin	-123.1%	-119	-53.46	-42.23	-38.04	-40.91	-34.60	-39.17	-46.65	-59.90	-99.85	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-37.4%	-54,188,000	-39,450,000	-44,839,000	-45,972,000	-40,734,000	-35,481,000	-39,161,000	-28,589,000	-13,630,000	-22,917,000	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	54.0%	978	635	642	293	314	352	385	422	333	351	209	217	164	183	200	217	124	130	143	155	167
Current Assets	59.8%	917	574	576	285	305	345	378	416	328	345	204	211	158	177	194	211	117	123	135	148	159
Cash Equivalents	623.6%	397	55.00	143	40.00	41.00	33.00	31.00	62.00	146	201	162	179	106	94.00	118	161	51.00	41.00	67.00	60.00	63.00
Net PPE	9.0%	12.00	11.00	10.00	3.00	3.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	4.00	4.00	4.00	4.00	4.00	4.00
Liabilities	7.2%	103	96.00	94.00	39.00	34.00	36.00	34.00	36.00	30.00	19.00	16.00	15.00	14.00	15.00	13.00	14.00	15.00	13.00	13.00	13.00	14.00
Current Liabilities	17.8%	52.00	44.00	40.00	33.00	26.00	28.00	25.00	26.00	20.00	16.00	12.00	12.00	10.00	10.00	9.00	10.00	11.00	8.00	8.00	8.00	9.00
Shareholder's Equity	62.3%	875	539	548	254	280	316	351	386	303	332	194	201	149	169	187	203	108	117	130	142	152
Retained Earnings	-10.2%	-720	-653	-593	-536	-485	-439	-394	-352	-309	-275	-244	-216	-190	-167	-146	-127	-111	-93.80	-79.25	-64.82	-52.40
Shares Outstanding	15.2%	79.00	68.00	67.00	55.00	54.00	54.00	54.00	50.00	48.00	38.00	36.00	37.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	1,000	-	-	-	1,000	-	-	-	683	-	-	-	506	-	-	-	423	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-37.2%	-52,856	-38,515	-41,339	-45,735	-40,718	-35,207	-38,479	-27,976	-13,543	-22,899	-25,673	-19,949	-20,067	-15,938	-18,004	-15,855	-12,230	-13,447	-13,607	-12,568	-6,759
Share Based Compensation	15.8%	13,454	11,617	11,049	10,175	8,096	7,948	7,434	7,131	5,755	5,158	4,555	4,233	3,406	2,971	2,781	2,528	2,147	1,831	1,854	1,581	1,028
Cashflow From Investing	100.4%	309	-87,308	-193,296	31,436	48,755	36,853	6,822	-174,271	-43,384	-101,798	-7,025	19,838	32,502	-8,892	-24,832	17,602	16,339	-12,823	20,448	9,443	24,599
Cashflow From Financing	937.8%	393,574	37,925	337,877	12,658	484	115	1,076	118,992	1,780	163,856	15,463	73,303	57.00	97.00	-158	108,150	6,482	17.00	22.00	8.00	20.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CRNX Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenues	$ 640	$ 2,679
Operating expenses:
Research and development	53,341	38,468
General and administrative	20,828	12,189
Total operating expenses	74,169	50,657
Loss from operations	(73,529)	(47,978)
Other income (expense):
Interest income	7,320	2,038
Other expense, net	(251)	(55)
Total other income, net	7,069	1,983
Loss before equity method investment	(66,460)	(45,995)
Loss on equity method investment	(470)	0
Net loss	$ (66,930)	$ (45,995)
Net loss per share:
Net loss per share - basic	$ (0.93)	$ (0.85)
Net loss per share - diluted	$ (0.93)	$ (0.85)
Weighted average shares - basic	72,289	53,908
Weighted average shares - diluted	72,289	53,908
Other comprehensive income (loss):
Unrealized gain (loss) on investment securities	$ (827)	$ 1,417
Comprehensive loss	$ (67,757)	$ (44,578)

CRNX Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 395,924	$ 54,897
Investment securities	505,037	503,658
Prepaid expenses and other current assets	16,267	15,598
Total current assets	917,228	574,153
Property and equipment, net	11,865	10,881
Operating lease right-of-use assets	45,760	46,549
Investment in Radionetics	0	470
Restricted cash	1,300	1,300
Other assets	2,000	2,000
Total assets	978,153	635,353
Current liabilities:
Accounts payable and accrued expenses	28,683	23,196
Accrued compensation and related expenses	14,829	14,517
Deferred revenue	2,463	2,056
Operating lease liabilities	5,792	4,173
Total current liabilities	51,767	43,942
Operating lease liabilities, non-current	46,712	47,555
Deferred revenue, non-current	4,741	4,750
Total liabilities	103,220	96,247
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.001 par; 10,000 shares authorized; no shares issued or outstanding at March 31, 2024 or December 31, 2023	0	0
Common stock and paid-in capital, $0.001 par; 200,000 shares authorized; 78,539 shares issued and outstanding at March 31, 2024; 68,175 shares issued and outstanding at December 31, 2023	1,595,415	1,191,831
Accumulated other comprehensive loss	150	977
Accumulated deficit	(720,632)	(653,702)
Total stockholders’ equity	874,933	539,106
Total liabilities and stockholders’ equity	$ 978,153	$ 635,353

About Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). It is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. The company was incorporated in 2008 and is headquartered in San Diego, California.

CEO	Dr. R. Scott Struthers Ph.D.
WEBSITE	crinetics.com
INDUSTRY	Biotechnology
EMPLOYEES	210

Crinetics Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Crinetics Pharmaceuticals Inc? What does CRNX stand for in stocks?

CRNX is the stock ticker symbol of Crinetics Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Crinetics Pharmaceuticals Inc (CRNX)?

As of Mon May 13 2024, market cap of Crinetics Pharmaceuticals Inc is 3.78 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CRNX stock?

You can check CRNX's fair value in chart for subscribers.

What is the fair value of CRNX stock?

You can check CRNX's fair value in chart for subscribers. The fair value of Crinetics Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Crinetics Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CRNX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Crinetics Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether CRNX is over valued or under valued. Whether Crinetics Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Crinetics Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CRNX.

What is Crinetics Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 13 2024, CRNX's PE ratio (Price to Earnings) is -16.07 and Price to Sales (PS) ratio is 1.92 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CRNX PE ratio will change depending on the future growth rate expectations of investors.